Committed to Helping You Get Your Genentech Medicine

Knowing what to expect can make all the difference. We can help you through each step of getting your Genentech medicine.

Frequently Asked Questions

About PERJETA Access Solutions

PERJETA Access Solutions is a resource for people who take a Genentech medicine. We connect you to the medicine you need.

I Am Concerned About Paying for PERJETA

There may be options to help you get the Genentech medicine your doctor has prescribed. PERJETA Access Solutions can refer you to patient assistance options.

We have changed the name of GATCF to the Genentech Patient Foundation. We made this change to show our commitment to helping patients and to make it easier to remember.

Getting My Medicine

You might not be able to get your Genentech medicine right away. First, your doctor’s office or specialty pharmacy will have to check to make sure your health insurance plan covers your medicine. This is called a “benefits investigation.” They also might have to send some more information before your plan covers your medicine. This is called a “prior authorization.”

Enrolling in PERJETA Access Solutions

  1. You fill out the Patient Consent Form.
  2. Your doctor fills out the Prescriber Service Form. You do not have to fill out anything on this form.
  3. Your doctor sends both of these forms to PERJETA Access Solutions.

There are 3 ways to send us the Patient Consent Form:

  • Complete it online at Genentech-Access.com/PatientConsent
  • Fill out a paper copy and fax or mail it to us (or give it to your doctor to do so)
  • Text a picture of the completed form to  (650) 877-1111

The Patient Consent Form lets us discuss your health information with your doctor and your health insurance plan. We can’t work with you without a signed Patient Consent Form.

You do not need to do anything else, but your doctor does. He or she needs to submit the Prescriber Service Form. This form tells us your doctor wants to treat you with PERJETA. Make sure your doctor has sent us the Prescriber Service Form so you get help from us.

You do not need to fill out anything on the Prescriber Service Form.

The Patient Consent Form replaces the PAN. The PAN and the Patient Consent Form are valid for 3 years in all states (except Maryland, where it is valid for 1 year).

If your PAN is still valid, you do not need to fill out the Patient Consent Form yet.

My Health Plan Denied Coverage for PERJETA

If your health insurance plan will not cover your Genentech medicine, you and your doctor’s office can file an appeal. Contact your doctor to ask if you should file an appeal.

We have resources to help you and your doctor file an appeal.

We have resources to help you and your doctor file an appeal. You or your doctor’s office has to file the appeal directly with your health insurance plan.

This depends on your health insurance plan. You should ask your plan directly about its process. Sometimes the appeals process is quick. However, it can take several months if you have to appeal several times.

My Insurance Might Change

If your insurance changes while you’re taking your Genentech medicine, call us. We can help you understand your new coverage.

The Genentech Patient Foundation gives free Genentech medicine to people who don't have insurance coverage or who have financial concerns and to people who meet certain income criteria.

It is your and your doctor's responsibility to complete and submit all required paperwork to your health insurance plan. Genentech cannot guarantee your plan will cover any treatments.

PAN=Patient Authorization and Notice of Request for Transmission of Health Information to Genentech Access Solutions and Genentech® Access to Care Foundation.

Important Safety Information & Indication

See More Back to Top

What it Treats

What does PERJETA treat?

  • PERJETA® (pertuzumab) is approved for use in combination with Herceptin® (trastuzumab) and docetaxel in people who have HER2-positive breast cancer that has spread to different parts of the body (metastatic) and who have not received anti-HER2 therapy or chemotherapy for metastatic breast cancer.

PERJETA® (pertuzumab) is approved for use in combination with Herceptin® (trastuzumab) and chemotherapy for:

  • use prior to surgery (neoadjuvant treatment) in people with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (tumor is greater than 2 cm in diameter or node-positive). PERJETA should be used as part of a complete treatment regimen for early breast cancer.
  • use after surgery (adjuvant treatment) in people with HER2-positive early breast cancer that has a high likelihood of coming back.

Important Safety Information

  • PERJETA may cause heart problems, including those without symptoms (such as reduced heart function) and those with symptoms (such as congestive heart failure)
  • Receiving PERJETA during pregnancy can result in the death of an unborn baby and birth defects
    • If you think you may be pregnant, you should contact your healthcare provider immediately
    • If you are exposed to PERJETA during pregnancy, or become pregnant while receiving PERJETA or within 7 months following the last dose of PERJETA in combination with Herceptin, you are encouraged to enroll in the MotHER Pregnancy Registry by contacting 1-800-690-6720 or visiting http://www.motherpregnancyregistry.com/ and report PERJETA exposure to Genentech at 1-888-835-2555
  • PERJETA should not be used in patients who are allergic to pertuzumab or to any of the ingredients in PERJETA
  • Other possible serious and sometimes fatal side effects of PERJETA therapy include:
    • Infusion-related reactions
    • Severe allergic reactions (hypersensitivity reactions/anaphylaxis)
  • The most common side effects of PERJETA when given with Herceptin and docetaxel for treatment of breast cancer that has spread to other parts of the body (metastatic) are:
    • Diarrhea
    • Hair loss
    • Low levels of white blood cells with or without fever
    • Nausea
    • Feeling tired
    • Rash
    • Damage to the nerves (numbness, tingling, pain in hands/feet)
  • The most common side effects of PERJETA when given with Herceptin and chemotherapy as part of an early breast cancer regimen before surgery are:
    • Constipation
    • Damage to the nerves (numbness, tingling, pain in hands/feet)
    • Diarrhea
    • Feeling tired
    • Hair loss
    • Headache
    • Low levels of red blood cells
    • Low levels of white blood cells with or without fever
    • Low platelet count
    • Mouth blisters or sores
    • Nausea
    • Pain in the muscles
    • Vomiting
    • Weakness

Side effects may vary based on chemotherapy regimen.

  • The most common side effects of PERJETA when given with Herceptin and chemotherapy as part of an early breast cancer regimen after surgery are:
    • Diarrhea
    • Nausea
    • Hair Loss
    • Feeling tired
    • Damage to the nerves (numbness, tingling, pain in hands/feet)
    • Vomiting

You are encouraged to report side effects to Genentech and the FDA. You may report side effects to the FDA at 1-800-FDA-1088 or http://www.fda.gov/medwatch. You may also report side effects to Genentech at 1-888-835-2555.

Please see full Prescribing Information for additional Important Safety Information, including most serious side effects.